ArticleThe Prostate2023

Differential responses to taxanes and PARP inhibitors in ATM- versus BRCA2-mutated metastatic castrate-resistant prostate cancer.

Christopher T Su et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.